| 0 (0%) | 11-02 15:07 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.25 | 1-year : | 1.46 |
| Resists | First : | 1.07 | Second : | 1.25 |
| Pivot price | 0.91 |
|||
| Supports | First : | 0.78 | Second : | 0.64 |
| MAs | MA(5) : | 0.88  |
MA(20) : | 0.95 |
| MA(100) : | 1.08 |
MA(250) : | 1.63 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 32.3 |
D(3) : | 34.6 |
| RSI | RSI(14): 34.8 |
|||
| 52-week | High : | 3.3 | Low : | 0.75 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ CRDF ] has closed above bottom band by 13.7%. Bollinger Bands are 51.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.93 - 0.93 | 0.93 - 0.93 |
| Low: | 0.85 - 0.85 | 0.85 - 0.86 |
| Close: | 0.88 - 0.89 | 0.89 - 0.9 |
Tue, 27 Oct 2026
Cardiff Oncology Inc (CRDF) Stock Price Target & Forecast - TradingKey
Wed, 21 Oct 2026
FDA gives a drug for a rare blood cancer special status that may bring trial tax credits. - Stock Titan
Thu, 10 Sep 2026
Cardiff Oncology, Inc. (CRDF) Presents at 8th Annual RAS-Targeted Drug Development Summit - Slideshow - Seeking Alpha
Tue, 30 Jun 2026
Is Cardiff Oncology, Inc. (CRDF) Stock Undervalued Amid Legal Uncertainty and Future Cancer Drug Potential? - Yahoo Finance
Mon, 22 Jun 2026
CRDF: Phase II Update; Survival Advantage Extended - Yahoo Finance
Fri, 22 May 2026
CRDF: First Quarter 2026 Results - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 78 (M) |
| Held by Insiders | 7.538e+007 (%) |
| Held by Institutions | 6.1 (%) |
| Shares Short | 11,680 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.191e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -9 % |
| Return on Assets (ttm) | 245.1 % |
| Return on Equity (ttm) | -46.8 % |
| Qtrly Rev. Growth | 508000 % |
| Gross Profit (p.s.) | -9.93 |
| Sales Per Share | -66.27 |
| EBITDA (p.s.) | -2.45211e+007 |
| Qtrly Earnings Growth | -0.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -41 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 3.05 |
| Dividend | 0 |
| Forward Dividend | 1.207e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|